BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38270756)

  • 1. Expression Significance of Estrogen Receptor ER-α36 in Breast Cancer Treated by Chemotherapy: A Meta-Analysis.
    He E; Xia X; Quan H; Leng P
    Mol Biotechnol; 2024 May; 66(5):991-999. PubMed ID: 38270756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic value of ER-α36 expression in breast cancer patients treated with chemotherapy.
    Yu L; Ke W; Wang Y; Ding W; Wang B; Huang S; Chen J; Wang X; Wang Z; Shen P
    Steroids; 2014 Jun; 84():11-6. PubMed ID: 24632025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design.
    Adewumi AT; Mosebi S
    Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
    Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
    PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
    Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
    J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen
    Wang C; Zhang T; Wang K; Zhang S; Sun Q; Yang X
    Front Oncol; 2021; 11():712849. PubMed ID: 34336701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
    Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
    Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ER-α36 in breast cancer by typical xenoestrogens.
    Liu J; Xu Z; Ma X; Huang B; Pan X
    Tumour Biol; 2015 Sep; 36(10):7355-64. PubMed ID: 26337277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
    Zhang X; Deng H; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
    Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
    J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER-α36: a novel biomarker and potential therapeutic target in breast cancer.
    Su X; Xu X; Li G; Lin B; Cao J; Teng L
    Onco Targets Ther; 2014; 7():1525-33. PubMed ID: 25210466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
    Wang ZY; Yin L
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells.
    Sun Q; Liang Y; Zhang T; Wang K; Yang X
    Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
    Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
    PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas.
    Lee LM; Cao J; Deng H; Chen P; Gatalica Z; Wang ZY
    Anticancer Res; 2008; 28(1B):479-83. PubMed ID: 18383888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.
    Kang L; Guo Y; Zhang X; Meng J; Wang ZY
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.
    Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W
    Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.